Journal
CANCER
Volume 125, Issue 2, Pages 194-204Publisher
WILEY
DOI: 10.1002/cncr.31848
Keywords
acute lymphoblastic leukemia (ALL); BCR/ABL1-like; diagnosis; Ph-like; prognosis; tyrosine kinase inhibitors (TKIs)
Categories
Funding
- Associazione Italiana per la Ricerca sul 26 Cancro 5x1000 Special Program Molecular Clinical Oncology-Extension program 27 [10007]
- Finanziamento Medi Progetti Universitari 2015
Ask authors/readers for more resources
BCR/ABL1-like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B-lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that of true BCR/ABL1-positive cases, and have a heterogeneous genetic background and a poor outcome. Next-generation sequencing studies have demonstrated that the majority of patients carry rearrangements of tyrosine kinases or cytokine receptors and mutations of janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus opening the way to the possible use of targeted therapeutic approaches. However, several issues remain unresolved at both the diagnostic and therapeutic level, such as the definition of a standardized method to identify BCR/ABL1-like ALL and the design of ad hoc clinical trials examining tyrosine kinase inhibitors or other tailored treatments. These aspects are discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available